GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005109818 | Prostate | BPH | regulation of binding | 121/3107 | 363/18723 | 2.74e-15 | 4.14e-13 | 121 |
GO:001604910 | Prostate | BPH | cell growth | 139/3107 | 482/18723 | 7.53e-12 | 5.90e-10 | 139 |
GO:007149618 | Prostate | BPH | cellular response to external stimulus | 102/3107 | 320/18723 | 8.99e-12 | 6.79e-10 | 102 |
GO:003158910 | Prostate | BPH | cell-substrate adhesion | 110/3107 | 363/18723 | 4.64e-11 | 2.96e-09 | 110 |
GO:003166817 | Prostate | BPH | cellular response to extracellular stimulus | 79/3107 | 246/18723 | 1.32e-09 | 5.69e-08 | 79 |
GO:190165310 | Prostate | BPH | cellular response to peptide | 104/3107 | 359/18723 | 2.51e-09 | 1.00e-07 | 104 |
GO:004578518 | Prostate | BPH | positive regulation of cell adhesion | 120/3107 | 437/18723 | 5.22e-09 | 1.90e-07 | 120 |
GO:000166717 | Prostate | BPH | ameboidal-type cell migration | 128/3107 | 475/18723 | 5.69e-09 | 2.05e-07 | 128 |
GO:003444616 | Prostate | BPH | substrate adhesion-dependent cell spreading | 43/3107 | 108/18723 | 7.20e-09 | 2.50e-07 | 43 |
GO:00516569 | Prostate | BPH | establishment of organelle localization | 107/3107 | 390/18723 | 3.67e-08 | 1.03e-06 | 107 |
GO:000716010 | Prostate | BPH | cell-matrix adhesion | 72/3107 | 233/18723 | 4.17e-08 | 1.16e-06 | 72 |
GO:00506739 | Prostate | BPH | epithelial cell proliferation | 116/3107 | 437/18723 | 7.12e-08 | 1.85e-06 | 116 |
GO:00506789 | Prostate | BPH | regulation of epithelial cell proliferation | 104/3107 | 381/18723 | 7.52e-08 | 1.92e-06 | 104 |
GO:004339316 | Prostate | BPH | regulation of protein binding | 60/3107 | 196/18723 | 7.72e-07 | 1.45e-05 | 60 |
GO:005110017 | Prostate | BPH | negative regulation of binding | 52/3107 | 162/18723 | 8.41e-07 | 1.56e-05 | 52 |
GO:00072297 | Prostate | BPH | integrin-mediated signaling pathway | 37/3107 | 107/18723 | 4.53e-06 | 6.76e-05 | 37 |
GO:00516508 | Prostate | BPH | establishment of vesicle localization | 49/3107 | 161/18723 | 9.12e-06 | 1.28e-04 | 49 |
GO:002240716 | Prostate | BPH | regulation of cell-cell adhesion | 109/3107 | 448/18723 | 1.43e-05 | 1.85e-04 | 109 |
GO:00074924 | Prostate | BPH | endoderm development | 28/3107 | 77/18723 | 2.21e-05 | 2.67e-04 | 28 |
GO:00068989 | Prostate | BPH | receptor-mediated endocytosis | 66/3107 | 244/18723 | 2.34e-05 | 2.80e-04 | 66 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0451017 | Prostate | BPH | Focal adhesion | 85/1718 | 203/8465 | 1.17e-12 | 2.28e-11 | 1.41e-11 | 85 |
hsa051658 | Prostate | BPH | Human papillomavirus infection | 111/1718 | 331/8465 | 6.15e-09 | 7.81e-08 | 4.83e-08 | 111 |
hsa0481020 | Prostate | BPH | Regulation of actin cytoskeleton | 80/1718 | 229/8465 | 1.23e-07 | 1.31e-06 | 8.10e-07 | 80 |
hsa0513518 | Prostate | BPH | Yersinia infection | 49/1718 | 137/8465 | 1.65e-05 | 1.27e-04 | 7.86e-05 | 49 |
hsa041515 | Prostate | BPH | PI3K-Akt signaling pathway | 104/1718 | 354/8465 | 2.07e-05 | 1.55e-04 | 9.61e-05 | 104 |
hsa0467028 | Prostate | BPH | Leukocyte transendothelial migration | 41/1718 | 114/8465 | 6.86e-05 | 4.35e-04 | 2.69e-04 | 41 |
hsa045125 | Prostate | BPH | ECM-receptor interaction | 28/1718 | 89/8465 | 8.33e-03 | 2.64e-02 | 1.64e-02 | 28 |
hsa0514016 | Prostate | BPH | Leishmaniasis | 24/1718 | 77/8465 | 1.57e-02 | 4.42e-02 | 2.73e-02 | 24 |
hsa0451018 | Prostate | BPH | Focal adhesion | 85/1718 | 203/8465 | 1.17e-12 | 2.28e-11 | 1.41e-11 | 85 |
hsa0516513 | Prostate | BPH | Human papillomavirus infection | 111/1718 | 331/8465 | 6.15e-09 | 7.81e-08 | 4.83e-08 | 111 |
hsa04810110 | Prostate | BPH | Regulation of actin cytoskeleton | 80/1718 | 229/8465 | 1.23e-07 | 1.31e-06 | 8.10e-07 | 80 |
hsa0513519 | Prostate | BPH | Yersinia infection | 49/1718 | 137/8465 | 1.65e-05 | 1.27e-04 | 7.86e-05 | 49 |
hsa0415112 | Prostate | BPH | PI3K-Akt signaling pathway | 104/1718 | 354/8465 | 2.07e-05 | 1.55e-04 | 9.61e-05 | 104 |
hsa04670112 | Prostate | BPH | Leukocyte transendothelial migration | 41/1718 | 114/8465 | 6.86e-05 | 4.35e-04 | 2.69e-04 | 41 |
hsa0451212 | Prostate | BPH | ECM-receptor interaction | 28/1718 | 89/8465 | 8.33e-03 | 2.64e-02 | 1.64e-02 | 28 |
hsa0514017 | Prostate | BPH | Leishmaniasis | 24/1718 | 77/8465 | 1.57e-02 | 4.42e-02 | 2.73e-02 | 24 |
hsa0451025 | Prostate | Tumor | Focal adhesion | 84/1791 | 203/8465 | 3.44e-11 | 6.69e-10 | 4.15e-10 | 84 |
hsa0481025 | Prostate | Tumor | Regulation of actin cytoskeleton | 84/1791 | 229/8465 | 3.40e-08 | 4.17e-07 | 2.58e-07 | 84 |
hsa0516522 | Prostate | Tumor | Human papillomavirus infection | 110/1791 | 331/8465 | 1.31e-07 | 1.51e-06 | 9.36e-07 | 110 |
hsa0415122 | Prostate | Tumor | PI3K-Akt signaling pathway | 105/1791 | 354/8465 | 7.42e-05 | 5.30e-04 | 3.28e-04 | 105 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ITGA4 | SNV | Missense_Mutation | novel | c.1100G>A | p.Arg367Lys | p.R367K | P13612 | protein_coding | deleterious(0.02) | probably_damaging(0.996) | TCGA-CN-5369-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ITGA4 | SNV | Missense_Mutation | novel | c.658N>C | p.Tyr220His | p.Y220H | P13612 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CN-A497-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
ITGA4 | SNV | Missense_Mutation | novel | c.1753N>A | p.Pro585Thr | p.P585T | P13612 | protein_coding | tolerated(0.13) | benign(0.001) | TCGA-CN-A6V6-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | CR |
ITGA4 | SNV | Missense_Mutation | novel | c.35N>A | p.Arg12Gln | p.R12Q | P13612 | protein_coding | tolerated(0.22) | benign(0.001) | TCGA-CQ-5326-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
ITGA4 | SNV | Missense_Mutation | novel | c.2619N>C | p.Leu873Phe | p.L873F | P13612 | protein_coding | tolerated(0.65) | benign(0.012) | TCGA-CV-6960-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
ITGA4 | SNV | Missense_Mutation | rs201930987 | c.1702N>A | p.Val568Met | p.V568M | P13612 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-CV-A45W-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ITGA4 | SNV | Missense_Mutation | | c.1013N>T | p.Arg338Ile | p.R338I | P13612 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DQ-5625-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
ITGA4 | SNV | Missense_Mutation | | c.898N>G | p.Lys300Glu | p.K300E | P13612 | protein_coding | deleterious(0.02) | possibly_damaging(0.538) | TCGA-F7-A624-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ITGA4 | SNV | Missense_Mutation | novel | c.1965G>C | p.Lys655Asn | p.K655N | P13612 | protein_coding | deleterious(0.05) | possibly_damaging(0.607) | TCGA-H7-8501-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | unknown | CR |
ITGA4 | SNV | Missense_Mutation | novel | c.65N>C | p.Leu22Pro | p.L22P | P13612 | protein_coding | deleterious(0) | possibly_damaging(0.642) | TCGA-QK-A8Z8-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3676 | ITGA4 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME | | Vedolizmab | | |
3676 | ITGA4 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME | | PTG-100 | | |
3676 | ITGA4 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME | | VEDOLIZUMAB | VEDOLIZUMAB | |
3676 | ITGA4 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME | inhibitor | CHEMBL1743087 | VEDOLIZUMAB | |
3676 | ITGA4 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME | | NATALIZUMAB | NATALIZUMAB | |
3676 | ITGA4 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME | antibody | 178103204 | NATALIZUMAB | |
3676 | ITGA4 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME | | FIRATEGRAST | FIRATEGRAST | |
3676 | ITGA4 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME | | ATL1102 | | |
3676 | ITGA4 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME | | NATALIZUMAB | NATALIZUMAB | |
3676 | ITGA4 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME | antagonist | CHEMBL2104967 | FIRATEGRAST | |